Immune checkpoint inhibitors (ICIs), which boost the immune system’s capacity to attack cancer cells by blocking immune checkpoint proteins like PD-1 and CTLA-4, have achieved remarkable success across various cancer types, including melanoma, lung, and gastric cancers [29]. This evidence concerns the gene CTLA4 and cancer.